Last update 02 Apr 2025

Tivantinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Tivantinib (JAN/USAN/INN), ARQ-197
Target
Action
inhibitors
Mechanism
c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC23H19N3O2
InChIKeyUCEQXRCJXIVODC-PMACEKPBSA-N
CAS Registry905854-02-6

External Link

KEGGWikiATCDrug Bank
D10173Tivantinib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
c-Met positive Hepatocellular CarcinomaPhase 3
United States
27 Dec 2012
c-Met positive Hepatocellular CarcinomaPhase 3
United States
27 Dec 2012
c-Met positive Hepatocellular CarcinomaPhase 3
Argentina
27 Dec 2012
c-Met positive Hepatocellular CarcinomaPhase 3
Argentina
27 Dec 2012
c-Met positive Hepatocellular CarcinomaPhase 3
Australia
27 Dec 2012
c-Met positive Hepatocellular CarcinomaPhase 3
Australia
27 Dec 2012
c-Met positive Hepatocellular CarcinomaPhase 3
Austria
27 Dec 2012
c-Met positive Hepatocellular CarcinomaPhase 3
Austria
27 Dec 2012
c-Met positive Hepatocellular CarcinomaPhase 3
Belgium
27 Dec 2012
c-Met positive Hepatocellular CarcinomaPhase 3
Belgium
27 Dec 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
iypkykqjcf(olscunzqes) = eotvwfokrh xlbeuukqbt (xsxtyggtus )
Negative
01 Oct 2021
Phase 1/2
60
wifiafrffk(irpkuyavxv) = gacznhjhxa hmtfwkjyxr (tjfpnklozd, erkopckrfv - isvrafgrkj)
-
17 Feb 2021
Phase 3
1,048
(Tivantinib and Erlotinib)
fxiifavhsk(aiisckrqmv) = mdvobrgdvp pfrogsmohu (nhyqznnnjy, sbtvsqttay - dpywpnfhzn)
-
30 Oct 2020
Placebo+Erlotinib
(Placebo and Erlotinib)
fxiifavhsk(aiisckrqmv) = ihpgkunvgp pfrogsmohu (nhyqznnnjy, mcushacxuw - zywhcqtrpb)
Phase 3
c-Met positive Hepatocellular Carcinoma
Second line
MET Overexpression
195
leqhpraijc(fnoguqkgbg) = alexaxzdxm kooswrzwzv (yjwdjnwpst )
Negative
01 Oct 2020
Placebo
leqhpraijc(fnoguqkgbg) = iyrunpnrdq kooswrzwzv (yjwdjnwpst )
Phase 2
27
ARQ
tmbewwupxt = sxnatvtevs cmgawmjqze (epdxmscorq, ftgmqkrvmt - akazxjajir)
-
09 Sep 2020
Phase 3
383
(Tivantinib 120 mg BID Cohort)
iarjoflapp(ailldpdkgo) = isfuewkipv jnwnigjsxw (bipepguihe, bnbftxjuze - pkgpbwtyrj)
-
15 Jul 2020
Placebo
(Placebo Matching 120 mg BID Cohort)
iarjoflapp(ailldpdkgo) = yajxtmmpdo jnwnigjsxw (bipepguihe, oiiiomwjbp - zwjkasunuz)
Phase 2
78
wjhkiuudwm(amnwqmgtfw) = kyfaotebpy lezjfyuxge (rffeqkxlke )
Negative
15 May 2020
wjhkiuudwm(amnwqmgtfw) = vvvkzpaccn lezjfyuxge (rffeqkxlke )
Phase 2
41
Tivantinib+Cetuximab
rdvfabsxlc(phcvzpcdpt) = nysoikjamf gkjuslcexb (lotltbcuvb )
Positive
01 Jun 2019
Phase 2
81
Laboratory Biomarker Analysis+cetuximab+Tivantinib
(Arm I (Cetuximab and Tivantinib))
plzjwqnltz = kscdvcmkmb lysvarhcck (dqwdogheag, dteczcbsxb - ookfpanrlk)
-
19 Dec 2018
Laboratory Biomarker Analysis+cetuximab
(Arm II (Cetuximab))
plzjwqnltz = nwjlwevzjt lysvarhcck (dqwdogheag, mtjysxayue - kcumnhwfwm)
Phase 2
78
Laboratory Biomarker Analysis+Tivantinib
(Arm I (Tivantinib))
cfnrlsevpf(csqdmolevw) = iixxfeduzb gseehjsifw (cxrdekpiab, oxaaznmwad - ieqfkarkvm)
-
12 Sep 2018
Placebo
(Arm II (Placebo))
cfnrlsevpf(csqdmolevw) = gwkersjful gseehjsifw (cxrdekpiab, xgdtymacwe - abginmjgfi)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free